• TRADE NAME: Venclexta (AbbVie)
• INDICATIONS: Chronic lymphocytic leukemia in patients with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
  
• CLASS: BCL-2 inhibitor
• HALF-LIFE: 26 hours

FDA APPROVAL DATE: 04/11/2016

Amiodarone, Azithromycin, Bosentan, Captopril, Carbamazepine, Carvedilol, Ciprofloxacin, Clarithromycin, Conivaptan, Cyclosporine, Digoxin, Diltiazem, Dronedarone, Efavirenz, Erythromycin, Etravirine, Everolimus, Felodipine, Fluconazole, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Live vaccines, Lopinavir, Modafinil, Nafcillin, Phenytoin, Posaconazole, Quercetin, Quinidine, Ranolazine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Stong or moderate P-gp inhibitors or substrates, Strong or moderate CYP3A inducers or inhibitors, Telaprevir, Ticagrelor, Verapamil, Voriconazole

PREGNANCY CATEGORY: N/A
May cause fetal harm